Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-term Results of Two Phase III Randomized Controlled Trials

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Tore K Kvien
  • Philip G Conaghan
  • Laure Gossec
  • Vibeke Strand
  • Mikkel Østergaard
  • Denis Poddubnyy
  • Nicole Williams
  • Brian Porter
  • Abhijit Shete
  • Isabelle Gilloteau
  • Atul Deodhar
View graph of relations

OBJECTIVE: To investigate the longer-term effects of secukinumab 150 mg on fatigue in patients with ankylosing spondylitis (AS) in the MEASURE 1 study (up to 3 years) and the MEASURE 2 study (up to 2 years).

METHODS: Patients with active AS were randomized to secukinumab or placebo in MEASURE 1 (10 mg/kg intravenous [IV] followed by 150 mg subcutaneous) and MEASURE 2 (150 mg subcutaneous). Patients were naive to treatment with anti-tumor necrosis factor (anti-TNF-naive) therapy or had an inadequate response/intolerance to anti-TNF therapy (anti-TNF-IR). Fatigue was measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. Relationships between fatigue response and baseline characteristics and clinical/laboratory variables were explored.

RESULTS: Significant improvements in FACIT-F scores from baseline were observed with secukinumab across both studies versus placebo at week 16 (P < 0.05). Improvements were sustained through week 156 (MEASURE 1) and week 104 (MEASURE 2). Significantly more patients reported fatigue responses (FACIT-F improvement ≥4; observed data) with secukinumab 150 mg than with placebo at week 16 in both MEASURE 1 (P < 0.05) and MEASURE 2 (P < 0.01). Fatigue responses were achieved by 75.6% of patients receiving secukinumab at week 156 (MEASURE 1) and 81.4% at week 104 (MEASURE 2); these results were consistent in patients who were anti-TNF-naive (74.3% and 84.6%, respectively) and anti-TNF-IR (81.3% and 75.0%, respectively). Baseline characteristics did not predict improvement in fatigue consistently. Fatigue responses were moderately to strongly correlated with responses in several clinical measures, including the Assessment of SpondyloArthritis international Society (ASAS) 20%/40% improvement, ASAS5/6 responses, the Ankylosing Spondylitis Disease Activity Score with C-reactive protein level, the Bath Ankylosing Spondylitis Disease Activity Index, and the Short Form 36 health questionnaire scores.

CONCLUSION: Secukinumab provided rapid and sustained improvements in fatigue for up to 3 years, regardless of prior anti-TNF exposure.

Original languageEnglish
JournalArthritis Care & Research
Volume74
Issue number5
Pages (from-to)759-767
Number of pages9
ISSN2151-464X
DOIs
Publication statusPublished - May 2022

    Research areas

  • Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/adverse effects, Double-Blind Method, Humans, Randomized Controlled Trials as Topic, Spondylitis, Ankylosing/complications, Tumor Necrosis Factor Inhibitors

ID: 61762575